SEQENS Completes Transfer of Wavelength Activities to New Shareholder

SEQENS has completed the transfer of its Wavelength activities, including Wavelength Enterprises Ltd. in Israel, Wavelength Enterprises Inc. in the United States and Monolom India Pharma Private Limited in India, to a new shareholder. Wavelength, which joined the group in 2021, develops and manufactures generic active pharmaceutical ingredients and complex chemistry from its Petah Tikva headquarters and Neot Hovav manufacturing site in Israel. Monolom provides research and development support from Pune, India, and the business now operates under local ownership.

Key facts

Market context

Generic active pharmaceutical ingredients are the chemical building blocks that give finished medicines their therapeutic effect, and they are produced in large volumes by specialist contract and generic manufacturers. Demand is driven mainly by the pharmaceutical sector, particularly off-patent drugs where price competition is intense and buyers often qualify several suppliers for the same molecule. Ownership changes at API makers can matter to customers because they may affect quality systems, regulatory filings, capacity allocation and long-term supply commitments, even when day-to-day production continues. Buyers of generic APIs typically respond to such transitions by reviewing supplier qualification and dual-sourcing options. Complex chemistry capabilities, which combine multistep synthesis with process development, are valued because they are harder to replicate than simple commodity intermediates. Research and development support from linked service sites can also influence how quickly new molecules move into commercial production. For investors and procurement teams, the key questions after a transfer like this are usually continuity of operations, site-level compliance and how the new owner plans to allocate capacity across its customer base.

Source: official release on seqens.com. Summary and context written by Market Krystal.